Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover.

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• Macroautophagy (autophagy) is linked to cell death and cancer progression.
• Clinical trials combine autophagy inhibitors with other drugs to enhance cancer cell death.
• The molecular mechanisms underlying the combination therapy are not fully understood.

Purpose of the Study:

• To elucidate the transcriptional mechanism connecting autophagy and apoptosis.
• To investigate the role of FOXO3a in mediating the effects of autophagy inhibition on apoptosis.
• To explore the therapeutic potential of targeting this mechanism in cancer treatment.

Main Methods:

• Investigated the turnover of FOXO3a by basal autophagy.
• Analyzed the transcriptional regulation of BBC3/PUMA by FOXO3a.
• Evaluated the effect of autophagy inhibition on cancer cell apoptosis sensitization.
• Assessed the efficacy of combining an autophagy inhibitor with an MDM2-targeted drug in vivo.

Main Results:

• Autophagy inhibition leads to increased levels of the transcription factor FOXO3a.
• Increased FOXO3a stimulates the transcription of the pro-apoptotic gene BBC3/PUMA.
• Autophagy inhibition sensitizes tumor cells to chemotherapy drugs.
• Combining an autophagy inhibitor with an MDM2-targeted drug shifted its action from growth inhibition to apoptosis, reducing tumor burden.

Conclusions:

• A transcriptional feedback loop exists where autophagy regulates FOXO3a, which in turn regulates apoptosis.
• This mechanism explains how autophagy inhibition sensitizes cancer cells to chemotherapy.
• Targeting the link between autophagy and apoptosis via FOXO3a offers a promising strategy for improving anti-cancer therapies.